Lipophilic calcium antagonists in antiatherosclerotic therapy

Current atherosclerosis reports

Volumn 2, Issue 1, 2000, Pages 76-81

  Bellosta, Stefano ^a,b   Bernini, Franco ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; LACIDIPINE; LERCANIDIPINE;

ARTERIOSCLEROSIS; CARDIOVASCULAR SYSTEM; CELL DIVISION; CELL MOTION; CYTOLOGY; DRUG EFFECT; ENDOTHELIUM; HEART MUSCLE; HUMAN; LIPID METABOLISM; MACROPHAGE; PATHOLOGY; PHYSIOLOGY; REVIEW; SMOOTH MUSCLE;

ARTERIOSCLEROSIS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR SYSTEM; CELL DIVISION; CELL MOVEMENT; DIHYDROPYRIDINES; ENDOTHELIUM; HUMANS; LIPID METABOLISM; MACROPHAGES; MUSCLE, SMOOTH; MYOCARDIUM;

EID: 0033749978     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-000-0098-9     Document Type: Review

References (49)

1. 1. R Ross 1999 Atherosclerosis: an inflammatory disease N Engl J Med 340 115 126 9887164 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D 10.1056/NEJM199901143400207 Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115–126.
2. 2. E Falk PK Shah V Fuster 1995 Coronary plaque disruption Circulation 92 657 671 7634481 1:STN:280:DyaK2MzmtFWlsw%3D%3D Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995, 92:657–671.
3. 3. HM Loree RD Kamm RG Stringfellow 1992 Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels Circ Res 71 850 858 1516158 1:STN:280:DyaK38zos1Knsg%3D%3D Loree HM, Kamm RD, Stringfellow RG, et al.: Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992, 71:850–858.
4. 4. PD Richardson MJ Davies GVR Born 1989 Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques Lancet 2 941 944 2571862 1:STN:280:DyaK3c%2FhtlOgtw%3D%3D 10.1016/S0140-6736(89)90953-7 Richardson PD, Davies MJ, Born GVR, et al.: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989, 2:941–944.
5. 5. MJ Davies PD Richardson N Woolf 1993 Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content Br Heart J 69 377 381 8518056 1:STN:280:DyaK3s3pvVCktw%3D%3D Davies MJ, Richardson PD, Woolf N, et al.: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993, 69:377–381.
6. 6. CM Dollery JR McEwan AM Henney 1995 Matrix metalloproteinases and cardiovascular disease Circ Res 77 863 868 7554139 1:CAS:528:DyaK2MXovVKrt7s%3D Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995, 77:863–868.
7. 7. MP Bendeck N Zempo AW Clowes 1994 Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat Circ Res 75 539 545 8062427 1:CAS:528:DyaK2cXlsFClsb4%3D Bendeck MP, Zempo N, Clowes AW, et al.: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994, 75:539–545.
8. 8. F Bernini AL Catapano A Corsini 1989 Effects of calcium antagonists on lipids and atherosclerosis Am J Cardiol 64 1291 1331 10.1016/0002-9149(89)90970-3 Bernini F, Catapano AL, Corsini A, et al.: Effects of calcium antagonists on lipids and atherosclerosis. Am J Cardiol 1989, 64:1291–1331.
9. 9. PD Henry KI Bentley 1981 Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine J Clin Invest 68 1366 1369 7298856 1:CAS:528:DyaL38XlslI%3D Henry PD, Bentley KI: Suppression of atherogenesis in cholesterol-fed rabbits treated with nifedipine. J Clin Invest 1981, 68:1366–1369.
10. 10. G Schmitz J Hankowitz EM Kovacs 1991 Cellular processes in atherogenesis: potential targets of Ca2+ channel blockers Atherosclerosis 88 109 132 1654052 1:CAS:528:DyaK3MXlt1Khsbw%3D 10.1016/0021-9150(91)90074-D Schmitz G, Hankowitz J, Kovacs EM: Cellular processes in atherogenesis: potential targets of Ca2+ channel blockers. Atherosclerosis 1991, 88:109–132.
11. 11. F Bernini A Corsini M Raiteri 1993 Effects of lacidipine on experimental models of atherosclerosis J Hypertens 11 suppl 3 S61 S66 1:CAS:528:DyaK3sXks1alurc%3D 10.1097/00004872-199303001-00011 Bernini F, Corsini A, Raiteri M, et al.: Effects of lacidipine on experimental models of atherosclerosis. J Hypertens 1993, 11 (suppl 3):S61-S66.
12. 12. LG Herbette DG Rodhes RP Mason 1991 New approaches to drug design and delivery based on drug-membrane interactions Drug Design Delivery 7 75 118 1:CAS:528:DyaK3MXlsV2mu7c%3D Herbette LG, Rodhes DG, Mason RP: New approaches to drug design and delivery based on drug-membrane interactions. Drug Design Delivery 1991, 7:75–118.
13. 13. Tulenko TN: Atherogenic activity of excess membrane cholesterol in arterial smooth muscle and endothelial cells. J Am Coll Cardiol 1991, 17: 24A.
14. 14. RP Mason DM Moisey L Shajenko 1992 Cholesterol alters the binding of Ca2+ channels blockers to the membrane lipid bilayer Mol Pharmacol 41 315 321 1531693 1:CAS:528:DyaK38Xls1egtr0%3D Mason RP, Moisey DM, Shajenko L: Cholesterol alters the binding of Ca2+ channels blockers to the membrane lipid bilayer. Mol Pharmacol 1992, 41:315–321.
15. 15. LG Herbette M Vecchiarelli A Sartani 1998 Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance: updated molecular model to rationalize its pharmacokinetic properties Blood Pressure 7 suppl 2 10 17 10.1080/080370598438492 Herbette LG, Vecchiarelli M, Sartani A, et al.: Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance: updated molecular model to rationalize its pharmacokinetic properties. Blood Pressure 1998, 7 (suppl 2):10–17.
16. 16. LG Herbette G Gaviraghi T Tulenko 1993 Molecular interaction between lacidipine and biological membranes J Hypertens 11 suppl 1 S13 S19 1:CAS:528:DyaK3sXks1alurY%3D 10.1097/00004872-199303001-00003 Herbette LG, Gaviraghi G, Tulenko T, et al.: Molecular interaction between lacidipine and biological membranes. J Hypertens 1993, 11 (suppl 1):S13-S19.
17. 17. LG Herbette RP Mason T Tulenko 1994 Calcium antagonists and membrane binding: the unique properties of lacidipine PA Zwieten Van Research and Clinical Forums, vol 16 Wells Medical Kent, England 17 28 Herbette LG, Mason RP, Tulenko T: Calcium antagonists and membrane binding: the unique properties of lacidipine. In Research and Clinical Forums, vol 16. Edited by Van Zwieten PA. Kent, England: Wells Medical; 1994:17–28.
18. 18. T Godfraind 1994 Calcium antagonists and vasodilatation Pharmacol Ther 64 37 75 7846116 1:CAS:528:DyaK2cXmvFWrtr0%3D 10.1016/0163-7258(94)90033-7 Godfraind T: Calcium antagonists and vasodilatation. Pharmacol Ther 1994, 64:37–75.
19. 19. RA Jamis PJ Silver DJ Triggle 1987 Drug action and calcium regulation Adv Drug Res 16 309 591 Jamis RA, Silver PJ, Triggle DJ: Drug action and calcium regulation. Adv Drug Res 1987, 16:309–591.
20. 20. RP Mason S Campbell SD Wang 1989 A comparison of bilayer location and binding for the charged 1,4-dihydropyridine Ca2+ channel antagonist amlodipine with uncharged drugs of this class in cardiac and model membranes Mol Pharmacol 36 634 640 2554114 1:CAS:528:DyaK3cXjtVantw%3D%3D Mason RP, Campbell S, Wang SD, et al.: A comparison of bilayer location and binding for the charged 1,4-dihydropyridine Ca2+ channel antagonist amlodipine with uncharged drugs of this class in cardiac and model membranes. Mol Pharmacol 1989, 36:634–640.
21. 21. DR Abernethy J Gutkowaka LM Winterbottom 1990 Effects of amlodipine, along acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition Clin Pharmacol Ther 48 76 86 2142447 1:STN:280:DyaK3czhsFOrsw%3D%3D 10.1038/clpt.1990.120 Abernethy DR, Gutkowaka J, Winterbottom LM: Effects of amlodipine, along acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990, 48:76–86.
22. 22. A Daugherty DL Rateri G Schonfeld 1987 Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade Br J Pharmacol 91 113 118 3594069 1:CAS:528:DyaL2sXksFWku78%3D Daugherty A, Rateri DL, Schonfeld G, et al.: Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade. Br J Pharmacol 1987, 91:113–118.
23. 23. O Stein Y Stein 1987 Effect of verapamil on cholesteryl ester hydrolysis and reesterification in macrophages Arteriosclerosis 7 578 584 3689204 1:CAS:528:DyaL1cXkvFWiug%3D%3D Stein O, Stein Y: Effect of verapamil on cholesteryl ester hydrolysis and reesterification in macrophages. Arteriosclerosis 1987, 7:578–584.
24. 24. OR Etinjin DP Hajjar 1985 Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbits arterial smooth muscle cells J Clin Invest 75 1554 1558 10.1172/JCI111860 Etinjin OR, Hajjar DP: Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbits arterial smooth muscle cells. J Clin Invest 1985, 75:1554–1558.
25. 25. F Bernini M Canavesi E Bernardini 1997 Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies Br J Pharmacol 122 1209 1215 9401788 1:CAS:528:DyaK2sXnsFWltb8%3D 10.1038/sj.bjp.0701469 Bernini F, Canavesi M, Bernardini E, et al.: Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies. Br J Pharmacol 1997, 122:1209–1215.
26. 26. M Canavesi S Bellosta A Sartani 1999 The effect of lercanidipine on cholesterol esterification in macrophages is unrelated to calcium antagonism: is lipophilicity involved [abstract]? Pharm Res 39 suppl 89 89 Canavesi M, Bellosta S, Sartani A, et al.: The effect of lercanidipine on cholesterol esterification in macrophages is unrelated to calcium antagonism: is lipophilicity involved [abstract]? Pharm Res 1999, 39 (suppl):89.
27. 27. K Suckling EF Stange 1985 Role of acyl-CoA: cholesterol acyl-transferase in cellular cholesterol metabolism J Lipid Res 26 647 671 3897424 1:CAS:528:DyaL2MXks1yltrg%3D Suckling K, Stange EF: Role of acyl-CoA: cholesterol acyl-transferase in cellular cholesterol metabolism. J Lipid Res 1985, 26:647–671.
28. 28. Bellosta S, Canavesi M, Favari E, et al.: The calcium antagonist lacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. Arterioscl Thromb Vasc Biol in press.
29. 29. DL Brown MS Hibbs M Kearney 1995 Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina Circulation 91 2125 2131 7697840 1:STN:280:DyaK2M3htF2ltA%3D%3D Brown DL, Hibbs MS, Kearney M, et al.: Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions: association of active enzyme synthesis with unstable angina. Circulation 1995, 91:2125–2131.
30. 30. LG Herbette G Gaviraghi T Tulenko 1993 Molecular interaction between lacidipine and biological membranes J Hypertens 11 S13 S19 1:CAS:528:DyaK3sXks1alurY%3D 10.1097/00004872-199303001-00003 Herbette LG, Gaviraghi G, Tulenko T, et al.: Molecular interaction between lacidipine and biological membranes. J Hypertens 1993, 11:S13-S19.
31. 31. ZS Galis K Asanuma D Godin 1998 N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 97 244 2453 Galis ZS, Asanuma K, Godin D, et al.: N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998, 97:244–2453.
32. 32. FTM Amsterdam Van A Roveri M Maiorino 1992 Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity Free Radical Biol Med 12 183 187 10.1016/0891-5849(92)90025-C Van Amsterdam FTM, Roveri A, Maiorino M, et al.: Lacidipine: a dihydropyridine calcium antagonist with antioxidant activity. Free Radical Biol Med 1992, 12:183–187.
33. 33. A Corsini MR Accomazzo M Canavesi 1998 The new calcium antagonist lercanidipine and its enentiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Pressure 7 suppl 2 1 5 Corsini A, Accomazzo MR, Canavesi M, et al.: The new calcium antagonist lercanidipine and its enentiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Pressure 1998, 7 (suppl 2):1–5.
34. 34. M Bonfatti V Castiglioni MR Soma 1995 Lacidipine inhibits arterial myocyte proliferation through a specific modulation of the G1 phase of the cell cycle [abstract] Pharm Res 31 suppl 228 228 10.1016/1043-6618(95)87171-3 Bonfatti M, Castiglioni V, Soma MR, et al.: Lacidipine inhibits arterial myocyte proliferation through a specific modulation of the G1 phase of the cell cycle [abstract]. Pharm Res 1995; 31 (suppl):228.
35. 35. A Corsini M Bonfatti P Quarato 1996 Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes J Cardiovasc Pharmacol 28 687 694 8945683 1:CAS:528:DyaK28Xnt1elurY%3D 10.1097/00005344-199611000-00012 Corsini A, Bonfatti M, Quarato P, et al.: Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol 1996, 28:687–694.
36. 36. MR Soma E Donetti R Seregni 1996 Effect of lacidipine and proliferative lesions induced in hypercholesterolemic rabbits Br J Pharmacol 118 215 219 8735617 1:CAS:528:DyaK28Xjt1Ojtbo%3D Soma MR, Donetti E, Seregni R, et al.: Effect of lacidipine and proliferative lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1996, 118:215–219.
37. 37. MR Soma M Natali E Donetti 1998 Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits Br J Pharmacol 125 1471 1476 9884075 1:CAS:528:DyaK1MXhtFSgtg%3D%3D 10.1038/sj.bjp.0702221 Soma MR, Natali M, Donetti E, et al.: Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol 1998, 125:1471–1476.
38. 38. Tulenko T, Mason RP, Chen M, et al.: Atherogenic activity caused by excess membrane cholesterol in arterial smooth muscle: role of calcium channels. In Fifth International Conference on Calcium Channels. Edited by Paoletti R, Godfraind T, Vanhoutte PM. New York: Raven.
39. 39. M Gleason M Medow T Tulenko 1991 Excess membrane cholesterol alters calcium movements, cytosolic calcium levels and membrane fluidity in arterial smooth muscle cells Circ Res 69 216 227 2054935 1:CAS:528:DyaK3MXkvFSgsro%3D Gleason M, Medow M, Tulenko T: Excess membrane cholesterol alters calcium movements, cytosolic calcium levels and membrane fluidity in arterial smooth muscle cells. Circ Res 1991, 69:216–227.
40. 40. T Godfraind S Salomone 1996 Calcium antagonists and endothelial function: focus on nitric oxide and endothelin Cardiovasc Drugs Ther 10 4 439 446 8924057 1:STN:280:DyaK2s%2Fot1ylsw%3D%3D 10.1007/BF00051108 Godfraind T, Salomone S: Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc Drugs Ther 1996, 10 (4):439–446.
41. 41. O Refron S Salomone T Godfraind 1996 Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats Br J Pharmacol 118 659 664 Refron O, Salomone S, Godfraind T: Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats. Br J Pharmacol 1996, 118:659–664.
42. 42. O Refron S Salomone T Godfraind 1995 Blood pressure-independent inhibition by lacidipine of endothelin-1 related cardiac hypertrophy in salt-loaded, stroke-prone spontaneously hypertensive rats J Cardiovasc Pharmacol 26 suppl 3 S459 S461 Refron O, Salomone S, Godfraind T: Blood pressure-independent inhibition by lacidipine of endothelin-1 related cardiac hypertrophy in salt-loaded, stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995, 26 (suppl 3):S459-S461.
43. 43. C Napoli R Paternò FM Faraci 1997 Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery Stroke 28 2266 2272 9368575 1:CAS:528:DyaK2sXnsFWrsLk%3D Napoli C, Paternò R, Faraci FM, et al.: Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery. Stroke 1997, 28:2266–2272.
44. 44. T Finkel 1998 Oxygen radicals and signaling Curr Opin Cell Biol 10 248 253 9561849 1:CAS:528:DyaK1cXisFyntLY%3D 10.1016/S0955-0674(98)80147-6 Finkel T: Oxygen radicals and signaling. Curr Opin Cell Biol 1998, 10:248–253.
45. 45. C Napoli S Salomone T Godfraind 1999 1,4-dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats Stroke 30 1907 1915 10471444 1:CAS:528:DyaK1MXmtFKmu7s%3D Napoli C, Salomone S, Godfraind T, et al.: 1,4-dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke 1999, 30:1907–1915.
46. 46. RP Mason T Mak MW Trumbore 1999 Antioxidant properties of calcium antagonists related to membrane biophysical interactions Am J Cardiol 84 16L 22L 10480441 1:CAS:528:DyaK1MXmtlyhtb8%3D 10.1016/S0002-9149(99)00360-4 Mason RP, Mak T, Trumbore MW, et al.: Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol 1999, 84:16L-22L.
47. 47. L Cominacini U Garbin AF Pasini 1997 Lacidipine inhibits the activation of the transcription factor NF-kB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells J Hypertens 15 1633 1639 9488215 1:CAS:528:DyaK1cXoslaqsA%3D%3D 10.1097/00004872-199715120-00065 Cominacini L, Garbin U, Pasini AF, et al.: Lacidipine inhibits the activation of the transcription factor NF-kB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997, 15:1633–1639.
48. 48. HM Himmel AR Whorton HC Strauss 1993 Intracellular calcium, currents and stimulus: response coupling in endothelial cell Hypertension 21 112 127 8380279 1:CAS:528:DyaK3sXnslGqtQ%3D%3D Himmel HM, Whorton AR, Strauss HC: Intracellular calcium, currents and stimulus: response coupling in endothelial cell. Hypertension 1993, 21:112–127.
49. 49. L Cominacini U Garbin AF Pasini 1998 Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine J Hypertens 16 1913 1919 9886877 1:CAS:528:DyaK1MXmtVelug%3D%3D 10.1097/00004872-199816121-00010 Cominacini L, Garbin U, Pasini AF, et al.: Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J Hypertens 1998, 16:1913–1919.